Author : adminDate : 2020-04-03 21:18

Main Contents from William Hearl's interview with the Washington Business Journal

In relation to the recent COVID-19 incident and vaccine development, the Washington Business Journal focused on Immunomic Therapeutics Inc. (IT) through an interview with President William Hearl on April 3rd.

The following is a summary of the main contents of the interview.


1. About Glioblastoma Multiforme (GBM)

- It is expected that the brain tumor treatment that IT is developing can be delivered to patients from 2022 through a rapid approval program.

- IT is currently developing nucleic acid-based glioblastoma treatments, which are off-the-shelf treatments that are inexpensive and have great patient convenience, as well as a cell therapy currently in Phase II clinical trial.

- Nucleic acid therapy is a drug that can be treated immediately after diagnosis.


2. About brain center

- IT plans to establish brain tumor centers not only in the United States but also overseas, including Korea, through brain tumor programs.

- HLB will discuss after completing investment in IT, and plan to discuss with HLB in detail after adjusting the publication rights across the country.


3. About COVID-19

 Immunomic Therapeutics

- IT is a Maryland-based biotechnology company that HLB has gained a significant interest in January and William Hearl is the founder and CEO of ITI. (ITI)


- Hearl started a business with Dr. J. Thomas August of Johns Hopkins University in Maryland in 2006 and has an immunotherapy vaccine platform technology called Universal Intracellular Targeted Expression (UNITE).

- UNITE has data that supports its application to SARS against the SARS virus in a paper by Dr. August and based on these technologies, it started to develop the COVID-19 vaccine, which is SARS' modified virus.

- IT has exported allergy treatment developed based on UNITE to Astellas Pharma for USD 315 Million (upfront), and if commercialized, it will receive continuous royalty.

- IT is currently developing a brain tumor treatment based on UNITE, and if the results of Phase 2 clinical trials are similar to those of Phase 1, we expect that commercialization as an innovative new drug or large-scale L / O will be possible.

- The ongoing clinical trials are expected to be completed fully enrolled within this year.